Dissolution testing has emerged in the pharmaceutical field as a very important tool to characterize drug product performance. Ciprofloxacin HCl as a frequently used antibiotic and has no validated dissolution method in its monograph. In vitro dissolution tests of solid oral dosage forms of ciprofloxacin were performed by various methods using different test conditions but always under "sink"conditions. Release profiles of different dosage forms of ciprofloxacin show that release rate in ph 1.2 is complete as compared to ph 6.8, 7.4. the release is much faster in the ph 1.2 and hence absorption of ciprofloxacin from stomach is maximum. The different conditions used were ph 1.2, 6.8, 7.4 and rpm of 100 and 75 respectively. The t80% and t 50% was calculated and compared.
Introduction
To ensure compliance with quality and safety standards, the United States, Europe, Japan, India and other countries have published compendia, or pharmacopeias, that describe official test methods for many marketed drug products. For example, compendia analytical methods found in United States Pharmacopeia 25 (USP 25) are legally recognized analytical procedures under section 501 (b) of the Federal Food, Drug, and Cosmetic Act. For these compendia methods, USP provides regulatory guidance for method validation. In addition, validation of analytical methods is covered by the United States Code of Federal Regulations (CFR) [1] [2] [3] .
Method validation is defined as the process of proving (through scientific studies) that an analytical method is acceptable for its intended use. 
Material and Methods

Materials
Ciprofloxacin tablets were procured from the local market. All chemicals were of analytical grade. Double distilled water was used throughout the experiment.
Dissolution test conditions and analysis procedure
Dissolution studies on one commercially available product (film coated tablets) of ciprofloxacin HCl were conducted using USP Apparatus (paddle method, Erweka DT80, Germany). The dissolution medium was 900 mL of either pH 1.2 hydrochloric acid aqueous solution, or pH 7.4 phosphate buffer or pH 6.8 at 37 ± 0.5 ˚C and stirred at 75 and 100 rpm. In all experiments, 5 ml sample aliquots were withdrawn at 5, 10, 20, 30 and 45 minutes and replaced with an equal volume of the fresh medium to maintain a constant total volume. Samples were assayed by the UV spectrophotometric method. Cumulative percentages of the drug dissolved from the products were calculated and plotted vs. time 10,11 .
Results and Discussions
The dissolution method development and validation was performed and it was found that % drug release in case of ciprofloxacin was found out to be more and faster in case of ph 1.2 as compared to ph 6.8 and 7.4. The release studies show that the mechanism of release was anomalous and the best fit model was a mixture of hixon crowell and first order release. The t50% was found to be in the following order ph 1.2>6.8>7.4 and similarly t 80% ph1.2>6.8>7.4. The t50% in case of ph 1.2 was found to be 10 mins and t80% of 27 mins.
Conclusion
Dissolution testing plays a very important role as an in-vitro test for evaluating drug products. Developing and validating dissolution test procedures can be a challenging process, on multiple fronts. Methods must be developed and validated not just for the dissolution test procedure itself, but also for any assay used to evaluate the test results. However, like any task, a systematic and methodical approach taking into account all the components that make up the dissolution test procedure, including the dissolution medium, the choice of apparatus, the test design (including the acceptance criteria), and determining the assay mode will pay great dividends in the end. There are only a few principle differences concerning validation of dissolution methods in the fields of pharmacokinetic studies and in quality control. 
